UK researchers are working to produce the first ovarian cancer vaccine in the aim of eradicating the illness globally. Researchers at the University of Oxford are developing a vaccine called OvarianVax to aid the immune system in identifying and combating ovarian cancer when it comes to its early stages.The important strides in immunization that were made in response to the Covid pandemic are being built upon by the preventative therapy. Despite their optimism that they would succeed in their goal of developing a therapy that might eradicate the disease, early projections indicate that it may take up to five years to make any real progress toward that end.A vaccine for ovarian cancer is being developed by Dr A Ahmed, a professor at the MRC Weatherall Institute of Molecular Medicine at the University of Oxford. The vaccine could save thousands of lives every year, as only 35% of women survive ten years after diagnosis. The vaccine could offer a less drastic option for women with genetic markers for ovarian cancer, allowing them to preserve fertility and avoid the health impacts of early menopause while still protecting against cancer. The research is being funded by Cancer Research UK over the next UK year, with its chief executive, Michelle Mitchell, praising the milestone research as an "exciting step forwards" as it focuses on preventing the first few cancer cells that develop. The vaccine is expected to be widely available in the coming years.